Survival Significance of Molecular Pathology and Genetic Variation in Brain Gliomas

Zhengzhou University

Status: Enrolling

Conditions: Molecular Sequence Variation; Glioma; Genetic Change

Treatments: Diagnostic Test: Glioma groups based on molecular pathology or genetic variation

Study type: Observational

Funder types: Other

Identifiers

NCT04216537

GiomaMG-1

Details and patient eligibility

About

This study aims to collect clinical, radiological, pathological, molecular and genetic data including detailed clinical parameters, MR and histopathology images, molecular pathology and genetic data. This study seeks to find the prognostic and clinical significance based on molecular and genetic biomarkers/subgroups of gliomas.

Full description

Precise classification based on molecular and genetic biomarkers/subgroups for gliomas is challenging. This study aims to collect clinical, radiological, pathological, molecular and genetic data including detailed clinical parameters, MR and histopathology images, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and genetic data (Whole exome sequencing, RNA sequencing, proteomics, etc). This study seeks to find the prognostic and clinical significance based on molecular and genetic biomarkers/subgroups of gliomas.

Enrollment: 3,000 estimated patients

Sex: All

Ages: 1 to 95 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must have radiologically and histologically confirmed diagnosis of primary glioma
• Life expectancy of greater than 3 months
• Must receive tumor resection
• Must have sufficient fresh frozen tissues for NGS
• Signed informed consent

Exclusion criteria

• No gliomas
• No sufficient amount of tumor tissues for detection of molecular pathology
• Patients who are pregnant or breast feeding
• Patients who are suffered from severe systematic malfunctions
• Do not have sufficient fresh frozen tissues for NGS